Recent Clinical Highlights and Upcoming Milestones: OCS-01 [Google translation] (GlobeNewswire) - Mar 4, 2026 - "Both Phase 3 DIAMOND trials with OCS-01, which aims to be the first eye drop therapy for DME, have enrolled over 800 patients and are nearing completion. Topline results are expected in Q2 2026, and, if positive, a subsequent NDA submission to the FDA is planned for Q4 2026. "
P2/3 data • P3 data: top line • Diabetic Macular Edema
|